About Ceterix
Ceterix is a Healthcare company based in Menlo Park (United States) founded in 2010, and was acquired by Smith & Nephew in December 2018. Novel suture passers for arthroscopic orthopedic surgery are developed. Ceterix has raised $73.88 million across 4 funding rounds from investors including SVB, Smith & Nephew and Oxford Finance. The company has 63 employees. Ceterix offers products and services including OxiSelectâ„¢ Assay Kits, Antibodies, Recombinant Proteins, and Cell Culture Reagents. Its focus areas include Life Sciences, Surgical Instruments, Surgical Access and Closure and Surgical Sutures. Its legal entity is CETERIX ORTHOPAEDICS, INC. Its competitors include SentreHEART, Tepha and SuturTek Incorporated; 3 of its 3 listed competitors have raised funding.
Company details
Ceterix Orthopaedics was founded in 2010 and is headquartered in Menlo Park, United States. Surgical tools for arthroscopic procedures in the orthopedic sector are developed by the company, with a focus on enabling stitches in tight joint spaces while safeguarding nerves, arteries, and cartilage. The NovoStitch suture passer is utilized for soft tissue suturing in hip and shoulder surgeries. FDA clearance for a suture cartridge was obtained in August 2018.
- Headquarters Menlo Park, United States
- Employees 63
- Stage Acquired
- SectorsHealthcare
- Website ceterix.com
- Social LinkedIn X
- Acquired by Smith & Nephew (Dec 2018)
- Legal Name Ceterix Orthopaedics, Inc
- Total Equity Funding$73.88M (USD)
in 4 rounds
- Latest Funding Round$23.04M (USD), Series C
Dec 2016
- InvestorsSVB
& 6 more
- Employee Count63
- Acquired bySmith & Nephew
(Dec 2018)
Products & Services of Ceterix
Ceterix offers a comprehensive portfolio of products and services, including OxiSelect™ Assay Kits, Antibodies, Recombinant Proteins, and Cell Culture Reagents.
Kits for measuring reactive oxygen species and lipid peroxidation
Antibodies for detecting proteins in biological samples
Proteins for cell biology and biochemistry research
Reagents to support cell growth and analysis
Funding Insights of Ceterix
Ceterix has successfully raised a total of $73.88M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $23.04 million completed in December 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $73.88M
- Total Rounds 4
- Last Round Series C — $23.04M
- First Round $19.5M
(Jan 2013)
- Investors Count 6
All 4 funding rounds of Ceterix with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2016 | $23.04M | Series C | – | – | – |
| May 2015 | $35M | Debt – Conventional | – | – | |
| Apr 2014 | $31.34M | Series B | – | – | |
| Jan 2013 | $19.5M | Series B | – | – |
7 investors in total: 7 institutional.
Investors in Ceterix
Ceterix has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Smith & Nephew and Oxford Finance.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
CRG is recognized as a premier healthcare investment partner. | crglp.com | Houston, United States | ||
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Venture capital fund backed incubator focused on the healthcare startups | 5amventures.com | San Francisco, United States | ||
Venture debt firm focused on the life sciences sector | 2002 | oxfordfinance.com | Alexandria, United States | |
Private equity and venture capital fund focused on the healthcare sector | novoholdings.dk | Hellerup, Denmark | ||
Banking services are provided to innovative companies, investors, and individuals. | 1983 | svb.com | Santa Clara, United States | |
Manufacturer of knee, hip and shoulder joint replacements | 1856 | smith-nephew.com | London, United Kingdom |
Investor details for Ceterix
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ceterix
162 people are tracked at Ceterix (86 in leadership, 12 in board & advisors, 64 in team); the tracked headcount is 63.
| Name | Role | Group |
|---|---|---|
Deepak Nath | CEO | Leadership |
Ram Subbu | International Distribution Director | Leadership |
Anne-Françoise Nesmes | CFO | Leadership |
Mizanu Kebede | Chief Quality & Regulatory Affairs Officer | Leadership |
Paul Connolly | President of Global Operations | Leadership |
Elga Lohler | Chief Human Resources Officer | Leadership |
Vasant Padmanabhan | President of Research & Development | Leadership |
Alison Parkes | Chief Compliance Officer | Leadership |
Brad Cannon | President of Orthopaedics, Sports Medicine & ENT & Americas | Leadership |
Douglas Wickstead | Sr. Director Program Manager | Leadership |
Rohit Kashyap | President Advanced Wound Management & Global Commercial Operations | Leadership |
Veronica Apostolico | Vice President, Internal Communication And Employee Engagement | Leadership |
Carlos Rodriguez | Chief Technical Architect | Leadership |
Lori Fontaine | Vice President, Global Clinical Strategy - Orthopaedics, Sports Medicine & ENT | Leadership |
David Nygren | VP AWM Growth Opportunities | Leadership |
Graeme Dilley | Global Category Director (professional Services) And Sourcing & Contracting Team Lead | Leadership |
Elizabeth Bennert | Director, Gct+e Curriculum Lead Sports Medicine + ENT | Leadership |
Ryan Emery | Vice President, Medical Education, Orthopaedics | Leadership |
Khilola Shukurova | Vice President Marketing, EMEA (orthopaedic Reconstruction, Sports Medicine, Wound Management) | Leadership |
Chip Elias | Vice President Bio Tissue - US West Area | Leadership |
142 more people are available in the full profile.
Complete people profiles for Ceterix
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ceterix
4 dated milestones of Ceterix across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Ceterix is founded.
- Funding First funding round of $19.5M.
- Funding Latest funding round, Series C, of $23.0M.
- Exit Acquired by Smith & Nephew.
Competitors of Ceterix
Ceterix has 3 listed competitors in our database, 3 of them funded. They include SentreHEART, Tepha and SuturTek Incorporated.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sentreheart.com | 2005 | Redwood, United States | $69.02M | Suture-based devices for soft tissue closure are developed. | ||
| tepha.com | 1998 | Lexington, United States | $36.31M | 51 | Absorbable biomaterials for medical sutures and meshes are developed. | |
| suturtek.com | 1993 | Chelmsford, United States | $1.4M | Suturing devices are supplied for open and minimally invasive surgery. |
Detailed competitors of Ceterix
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Medical Equipment & Supplies
3 companies that operate in the same segment as Ceterix (Medical Equipment & Supplies) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Robotic waterjet system for prostate tissue removal is developed. | 2009 | Redwood City, California, United States | USD 348.84 M | USD 308.05 M | 756 | |
Robotic microsurgical systems for endoscopy are developed. | 2007 | Redwood City, California, United States | USD 733.62 M | 91 | ||
Injectable packaging, containment, and delivery solutions are manufactured. | 1923 | Exton, Pennsylvania, United States | USD 3.07 B | 10,600 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ceterix
Complete news archive for Ceterix
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ceterix
Ceterix was founded in 2010 and raised its 1st funding round 3 years after it was founded.
Ceterix is headquartered in Menlo Park, United States. It is registered at Menlo Park, California, United States.
Ceterix is a funded company, having raised a total of $73.88M across 4 funding rounds to date. The company's 1st funding round was a Series B of $19.5M, raised on Jan 2013.
Ceterix has 63 employees.
Ceterix Orthopaedics was founded in 2010 and is headquartered in Menlo Park, United States. Surgical tools for arthroscopic procedures in the orthopedic sector are developed by the company, with a focus on enabling stitches in tight joint spaces while safeguarding nerves, arteries, and cartilage. The NovoStitch suture passer is utilized for soft tissue suturing in hip and shoulder surgeries. FDA clearance for a suture cartridge was obtained in August 2018.
Ceterix's top competitors include SentreHEART, Tepha and SuturTek Incorporated.
Ceterix offers OxiSelectâ„¢ Assay Kits, Antibodies, Recombinant Proteins, and Cell Culture Reagents.
Ceterix has 7 investors. Key investors include SVB, Smith & Nephew, Oxford Finance, CRG, and Versant Ventures.
Ceterix operates through Ceterix Orthopaedics, Inc.
Yes. Ceterix was acquired by Smith & Nephew in December 2018.